Skip to main content
Top
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems

Authors: S Yousuf Zafar, Amy P Abernethy, David H Abbott, Steven C Grambow, Jennifer E Marcello, James E Herndon II, Krista L Rowe, Jane T Kolimaga, Leah L Zullig, Meenal B Patwardhan, Dawn T Provenzale

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Stage at diagnosis plays a significant role in colorectal cancer (CRC) survival. Understanding which factors contribute to a more advanced stage at diagnosis is vital to improving overall survival. Comorbidity, race, and age are known to impact receipt of cancer therapy and survival, but the relationship of these factors to stage at diagnosis of CRC is less clear. The objective of this study is to investigate how comorbidity, race and age influence stage of CRC diagnosis.

Methods

Two distinct healthcare populations in the United States (US) were retrospectively studied. Using the Cancer Care Outcomes Research and Surveillance Consortium database, we identified CRC patients treated at 15 Veterans Administration (VA) hospitals from 2003–2007. We assessed metastatic CRC patients treated from 2003–2006 at 10 non-VA, fee-for-service (FFS) practices. Stage at diagnosis was dichotomized (non-metastatic, metastatic). Race was dichotomized (white, non-white). Charlson comorbidity index and age at diagnosis were calculated. Associations between stage, comorbidity, race, and age were determined by logistic regression.

Results

342 VA and 340 FFS patients were included. Populations differed by the proportion of patients with metastatic CRC at diagnosis (VA 27% and FFS 77%) reflecting differences in eligibility criteria for inclusion. VA patients were mean (standard deviation; SD) age 67 (11), Charlson index 2.0 (1.0), and were 63% white. FFS patients were mean age 61 (13), Charlson index 1.6 (1.0), and were 73% white. In the VA cohort, higher comorbidity was associated with earlier stage at diagnosis after adjusting for age and race (odds ratio (OR) 0.76, 95% confidence interval (CI) 0.58–1.00; p = 0.045); no such significant relationship was identified in the FFS cohort (OR 1.09, 95% CI 0.82–1.44; p = 0.57). In both cohorts, no association was found between stage at diagnosis and either age or race.

Conclusion

Higher comorbidity may lead to earlier stage of CRC diagnosis. Multiple factors, perhaps including increased interactions with the healthcare system due to comorbidity, might contribute to this finding. Such increased interactions are seen among patients within a healthcare system like the VA system in the US versus sporadic interactions which may be seen with FFS healthcare.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007, 18 (3): 581-592. 10.1093/annonc/mdl498.CrossRefPubMed Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007, 18 (3): 581-592. 10.1093/annonc/mdl498.CrossRefPubMed
2.
go back to reference Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 34-66.CrossRef Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 34-66.CrossRef
4.
go back to reference Firat S, Pleister A, Byhardt RW, Gore E: Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). Am J Clin Oncol. 2006, 29 (3): 252-257. 10.1097/01.coc.0000217824.20290.ab.CrossRefPubMed Firat S, Pleister A, Byhardt RW, Gore E: Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). Am J Clin Oncol. 2006, 29 (3): 252-257. 10.1097/01.coc.0000217824.20290.ab.CrossRefPubMed
5.
go back to reference Hawfield A, Lovato J, Covington D, Kimmick G: Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting. Crit Rev Oncol Hematol. 2006, 59 (3): 250-255. 10.1016/j.critrevonc.2005.12.004.CrossRefPubMed Hawfield A, Lovato J, Covington D, Kimmick G: Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting. Crit Rev Oncol Hematol. 2006, 59 (3): 250-255. 10.1016/j.critrevonc.2005.12.004.CrossRefPubMed
6.
go back to reference Lemmens VE, van Halteren AH, Janssen-Heijnen ML, Vreugdenhil G, Repelaer van Driel OJ, Coebergh JW: Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Ann Oncol. 2005, 16 (5): 767-772. 10.1093/annonc/mdi159.CrossRefPubMed Lemmens VE, van Halteren AH, Janssen-Heijnen ML, Vreugdenhil G, Repelaer van Driel OJ, Coebergh JW: Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Ann Oncol. 2005, 16 (5): 767-772. 10.1093/annonc/mdi159.CrossRefPubMed
7.
go back to reference Seve P, Sawyer M, Hanson J, Broussolle C, Dumontet C, Mackey JR: The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer. 2006, 106 (9): 2058-2066. 10.1002/cncr.21833.CrossRefPubMed Seve P, Sawyer M, Hanson J, Broussolle C, Dumontet C, Mackey JR: The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer. 2006, 106 (9): 2058-2066. 10.1002/cncr.21833.CrossRefPubMed
8.
go back to reference Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM: Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol. 2006, 101 (10): 2308-2318. 10.1111/j.1572-0241.2006.00775.x.CrossRefPubMed Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM: Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol. 2006, 101 (10): 2308-2318. 10.1111/j.1572-0241.2006.00775.x.CrossRefPubMed
9.
go back to reference Griggs JJ, Culakova E, Sorbero ME, Poniewierski MS, Wolff DA, Crawford J, Dale DC, Lyman GH: Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007, 25 (18): 2522-2527. 10.1200/JCO.2006.10.2749.CrossRefPubMed Griggs JJ, Culakova E, Sorbero ME, Poniewierski MS, Wolff DA, Crawford J, Dale DC, Lyman GH: Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007, 25 (18): 2522-2527. 10.1200/JCO.2006.10.2749.CrossRefPubMed
10.
go back to reference Ramsey SD, Howlader N, Etzioni RD, Donato B: Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results. Medicare. J Clin Oncol. 2004, 22 (24): 4971-4978. 10.1200/JCO.2004.05.031.CrossRefPubMed Ramsey SD, Howlader N, Etzioni RD, Donato B: Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results. Medicare. J Clin Oncol. 2004, 22 (24): 4971-4978. 10.1200/JCO.2004.05.031.CrossRefPubMed
11.
go back to reference Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, Siegel R, Stewart A, Jemal A: Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008, 58 (1): 9-31. 10.3322/CA.2007.0011.CrossRefPubMed Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, Siegel R, Stewart A, Jemal A: Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008, 58 (1): 9-31. 10.3322/CA.2007.0011.CrossRefPubMed
12.
go back to reference Halpern MT, Bian J, Ward EM, Schrag NM, Chen AY: Insurance status and stage of cancer at diagnosis among women with breast cancer. Cancer. 2007, 110 (2): 403-411. 10.1002/cncr.22786.CrossRefPubMed Halpern MT, Bian J, Ward EM, Schrag NM, Chen AY: Insurance status and stage of cancer at diagnosis among women with breast cancer. Cancer. 2007, 110 (2): 403-411. 10.1002/cncr.22786.CrossRefPubMed
14.
go back to reference Oddone EZ, Petersen LA, Weinberger M, Freedman J, Kressin NR: Contribution of the Veterans Health Administration in understanding racial disparities in access and utilization of health care: a spirit of inquiry. Med Care. 2002, 40 (1 Suppl): I3-13.PubMed Oddone EZ, Petersen LA, Weinberger M, Freedman J, Kressin NR: Contribution of the Veterans Health Administration in understanding racial disparities in access and utilization of health care: a spirit of inquiry. Med Care. 2002, 40 (1 Suppl): I3-13.PubMed
15.
go back to reference Kerr EA, Gerzoff RB, Krein SL, Selby JV, Piette JD, Curb JD, Herman WH, Marrero DG, Narayan KM, Safford MM, et al: Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med. 2004, 141 (4): 272-281.CrossRefPubMed Kerr EA, Gerzoff RB, Krein SL, Selby JV, Piette JD, Curb JD, Herman WH, Marrero DG, Narayan KM, Safford MM, et al: Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med. 2004, 141 (4): 272-281.CrossRefPubMed
16.
go back to reference Jha AK, Perlin JB, Kizer KW, Dudley RA: Effect of the transformation of the Veterans Affairs Health Care System on the quality of care. N Engl J Med. 2003, 348 (22): 2218-2227. 10.1056/NEJMsa021899.CrossRefPubMed Jha AK, Perlin JB, Kizer KW, Dudley RA: Effect of the transformation of the Veterans Affairs Health Care System on the quality of care. N Engl J Med. 2003, 348 (22): 2218-2227. 10.1056/NEJMsa021899.CrossRefPubMed
17.
go back to reference Ayanian JZ, Chrischilles EA, Fletcher RH, Fouad MN, Harrington DP, Kahn KL, Kiefe CI, Lipscomb J, Malin JL, Potosky AL, et al: Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol. 2004, 22: 2992-2996. 10.1200/JCO.2004.06.020.CrossRefPubMed Ayanian JZ, Chrischilles EA, Fletcher RH, Fouad MN, Harrington DP, Kahn KL, Kiefe CI, Lipscomb J, Malin JL, Potosky AL, et al: Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol. 2004, 22: 2992-2996. 10.1200/JCO.2004.06.020.CrossRefPubMed
18.
go back to reference Abernethy AP, Patwardhan M, Herndon JE, Dowell J, Rowe K, Martin MG, Zafar YMAM: Tracking performance: Can oncology practices respond to the new quality measures?. American Society of Clinical Oncology Gastrointestinal Cancers Symposium: 2007; Orlando, FL. 2007 Abernethy AP, Patwardhan M, Herndon JE, Dowell J, Rowe K, Martin MG, Zafar YMAM: Tracking performance: Can oncology practices respond to the new quality measures?. American Society of Clinical Oncology Gastrointestinal Cancers Symposium: 2007; Orlando, FL. 2007
20.
go back to reference Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992, 45: 613-619. 10.1016/0895-4356(92)90133-8.CrossRefPubMed Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992, 45: 613-619. 10.1016/0895-4356(92)90133-8.CrossRefPubMed
21.
go back to reference Charlson ME, Pompei P, Ales Kl, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987, 40: 373-383. 10.1016/0021-9681(87)90171-8.CrossRefPubMed Charlson ME, Pompei P, Ales Kl, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987, 40: 373-383. 10.1016/0021-9681(87)90171-8.CrossRefPubMed
22.
go back to reference Galbraith RF: A note on graphical presentation of estimated odds ratios from several clinical trials. Statistics in medicine. 1988, 7 (8): 889-894. 10.1002/sim.4780070807.CrossRefPubMed Galbraith RF: A note on graphical presentation of estimated odds ratios from several clinical trials. Statistics in medicine. 1988, 7 (8): 889-894. 10.1002/sim.4780070807.CrossRefPubMed
23.
go back to reference Anthony T, Hynan LS, D R: The association of pretreatment health-related quality of life with surgical complications for patients undergoing open surgical resection for colorectal cancer. Ann Surg. 2003, 238: 690-696. 10.1097/01.sla.0000094304.17672.6e.CrossRefPubMedPubMedCentral Anthony T, Hynan LS, D R: The association of pretreatment health-related quality of life with surgical complications for patients undergoing open surgical resection for colorectal cancer. Ann Surg. 2003, 238: 690-696. 10.1097/01.sla.0000094304.17672.6e.CrossRefPubMedPubMedCentral
24.
go back to reference Bach PB, Schrag D, Brawley OW, et al: Survival of whites and blacks after a cancer diagnosis. JAMA. 2002, 287: 2106-2113. 10.1001/jama.287.16.2106.CrossRefPubMed Bach PB, Schrag D, Brawley OW, et al: Survival of whites and blacks after a cancer diagnosis. JAMA. 2002, 287: 2106-2113. 10.1001/jama.287.16.2106.CrossRefPubMed
25.
go back to reference Colorectal Cancer Collaborative Group: Surgery for colorectal cancer in elderly patients: a systematic review. Lancet. 2000, 356: 968-974. 10.1016/S0140-6736(00)02713-6.CrossRef Colorectal Cancer Collaborative Group: Surgery for colorectal cancer in elderly patients: a systematic review. Lancet. 2000, 356: 968-974. 10.1016/S0140-6736(00)02713-6.CrossRef
26.
go back to reference Luo R, Giordano SH, Freeman JL, et al: Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer. Oncologist. 2006, 11: 1025-1033. 10.1634/theoncologist.11-9-1025.CrossRefPubMedPubMedCentral Luo R, Giordano SH, Freeman JL, et al: Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer. Oncologist. 2006, 11: 1025-1033. 10.1634/theoncologist.11-9-1025.CrossRefPubMedPubMedCentral
27.
go back to reference Neugent AI, Matasar M, Wang X, et al: Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006, 24: 2368-2375. 10.1200/JCO.2005.04.5005.CrossRef Neugent AI, Matasar M, Wang X, et al: Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006, 24: 2368-2375. 10.1200/JCO.2005.04.5005.CrossRef
28.
go back to reference Ong S, Watters JM, E G: Predictors for referral for adjuvant therapy for colorectal cancer. Can J Surg. 2005, 48: 225-229.PubMedPubMedCentral Ong S, Watters JM, E G: Predictors for referral for adjuvant therapy for colorectal cancer. Can J Surg. 2005, 48: 225-229.PubMedPubMedCentral
29.
go back to reference Ouellette JR, Small DG, PM T: Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma. J Gastrointest Surg. 2004, 8: 1061-1067. 10.1016/j.gassur.2004.09.045.CrossRefPubMed Ouellette JR, Small DG, PM T: Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma. J Gastrointest Surg. 2004, 8: 1061-1067. 10.1016/j.gassur.2004.09.045.CrossRefPubMed
30.
go back to reference Gross CP, McAvay GJ, Guo Z, Tinetti ME: The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer. 2007, 109 (12): 2410-2419. 10.1002/cncr.22726.CrossRefPubMed Gross CP, McAvay GJ, Guo Z, Tinetti ME: The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer. 2007, 109 (12): 2410-2419. 10.1002/cncr.22726.CrossRefPubMed
31.
go back to reference Nelson KM, Chapko MK, Reiber G, Boyko EJ: The association between health insurance coverage and diabetes care; data from the 2000 Behavioral Risk Factor Surveillance System. Health Serv Res. 2005, 40 (2): 361-372. 10.1111/j.1475-6773.2005.0d362.x.CrossRefPubMedPubMedCentral Nelson KM, Chapko MK, Reiber G, Boyko EJ: The association between health insurance coverage and diabetes care; data from the 2000 Behavioral Risk Factor Surveillance System. Health Serv Res. 2005, 40 (2): 361-372. 10.1111/j.1475-6773.2005.0d362.x.CrossRefPubMedPubMedCentral
35.
go back to reference Wilson NJ, Kizer KW: The VA health care system: An unrecognized safety net. Health Aff. 1997, 16: 200-204. 10.1377/hlthaff.16.4.200.CrossRef Wilson NJ, Kizer KW: The VA health care system: An unrecognized safety net. Health Aff. 1997, 16: 200-204. 10.1377/hlthaff.16.4.200.CrossRef
36.
go back to reference Crawford J, Cohen HJ: Aging and neoplasia. Annu Rev Gerontol Geriatr. 1984, 4: 3-32.PubMed Crawford J, Cohen HJ: Aging and neoplasia. Annu Rev Gerontol Geriatr. 1984, 4: 3-32.PubMed
37.
go back to reference Yang YX, Hennessy S, Lewis JD: Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004, 127 (4): 1044-1050. 10.1053/j.gastro.2004.07.011.CrossRefPubMed Yang YX, Hennessy S, Lewis JD: Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004, 127 (4): 1044-1050. 10.1053/j.gastro.2004.07.011.CrossRefPubMed
38.
go back to reference Shayne M, Culakova E, Poniewierski MS, Wolff D, Dale DC, Crawford J, Lyman GH: Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007, 110 (7): 1611-1620. 10.1002/cncr.22939.CrossRefPubMed Shayne M, Culakova E, Poniewierski MS, Wolff D, Dale DC, Crawford J, Lyman GH: Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007, 110 (7): 1611-1620. 10.1002/cncr.22939.CrossRefPubMed
39.
go back to reference Berardi R, Saladino T, Mari D, Silva RR, Scartozzi M, Verdecchia L, Onofri A, Cascinu S: Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy. Tumori. 2005, 91 (6): 463-466.PubMed Berardi R, Saladino T, Mari D, Silva RR, Scartozzi M, Verdecchia L, Onofri A, Cascinu S: Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy. Tumori. 2005, 91 (6): 463-466.PubMed
40.
go back to reference Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006, 24 (25): 4085-4091. 10.1200/JCO.2006.06.9039.CrossRefPubMed Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006, 24 (25): 4085-4091. 10.1200/JCO.2006.06.9039.CrossRefPubMed
41.
go back to reference Sanoff HK, Bleiberg H, Goldberg RM: Managing older patients with colorectal cancer. J Clin Oncol. 2007, 25 (14): 1891-1897. 10.1200/JCO.2006.10.1220.CrossRefPubMed Sanoff HK, Bleiberg H, Goldberg RM: Managing older patients with colorectal cancer. J Clin Oncol. 2007, 25 (14): 1891-1897. 10.1200/JCO.2006.10.1220.CrossRefPubMed
42.
go back to reference Hall SF: A user's guide to selecting a comorbidity index for clinical research. J Clin Epidemiol. 2006, 59: 849-855. 10.1016/j.jclinepi.2005.11.013.CrossRefPubMed Hall SF: A user's guide to selecting a comorbidity index for clinical research. J Clin Epidemiol. 2006, 59: 849-855. 10.1016/j.jclinepi.2005.11.013.CrossRefPubMed
43.
go back to reference Cooper GS, Fortinsky RH, Hapke R, Landefeld CS: Primary care physician recommendations for colorectal cancer screening. Patient and practitioner factors. Arch Int Med. 1997, 157: 1946-1950. 10.1001/archinte.157.17.1946.CrossRef Cooper GS, Fortinsky RH, Hapke R, Landefeld CS: Primary care physician recommendations for colorectal cancer screening. Patient and practitioner factors. Arch Int Med. 1997, 157: 1946-1950. 10.1001/archinte.157.17.1946.CrossRef
44.
go back to reference Fisher DA, Judd L, Sanford NS: Inappropriate colorectal cancer screening: findings and implications. Am J Gastroenterol. 2005, 100 (11): 2526-2530. 10.1111/j.1572-0241.2005.00322.x.CrossRefPubMed Fisher DA, Judd L, Sanford NS: Inappropriate colorectal cancer screening: findings and implications. Am J Gastroenterol. 2005, 100 (11): 2526-2530. 10.1111/j.1572-0241.2005.00322.x.CrossRefPubMed
45.
go back to reference Garman KS, Jeffreys A, Coffman C, et al: Colorectal cancer screening, comorbidity, and follow-up in elderly patients. Am J Med Sci. 2006, 332: 159-163. 10.1097/00000441-200610000-00001.CrossRefPubMed Garman KS, Jeffreys A, Coffman C, et al: Colorectal cancer screening, comorbidity, and follow-up in elderly patients. Am J Med Sci. 2006, 332: 159-163. 10.1097/00000441-200610000-00001.CrossRefPubMed
46.
go back to reference Sultan S, Conway J, Edelman D, Dudley T, Provenzale D: Colorectal cancer screening in young patients with poor health and severe comorbidity. Arch Intern Med. 2006, 166 (20): 2209-2214. 10.1001/archinte.166.20.2209.CrossRefPubMed Sultan S, Conway J, Edelman D, Dudley T, Provenzale D: Colorectal cancer screening in young patients with poor health and severe comorbidity. Arch Intern Med. 2006, 166 (20): 2209-2214. 10.1001/archinte.166.20.2209.CrossRefPubMed
47.
go back to reference Subramanian S, Klosterman M, Amonkar MM, Hunt TL: Adherence with colorectal cancer screening guidelines: a review. Prev Med. 2004, 38 (5): 536-550. 10.1016/j.ypmed.2003.12.011.CrossRefPubMed Subramanian S, Klosterman M, Amonkar MM, Hunt TL: Adherence with colorectal cancer screening guidelines: a review. Prev Med. 2004, 38 (5): 536-550. 10.1016/j.ypmed.2003.12.011.CrossRefPubMed
48.
go back to reference Dolan NC, Ferreira MR, Fitzgibbon ML, Davis TC, Rademaker AW, Liu D, Lee J, Wolf M, Schmitt BP, Bennett CL: Colorectal cancer screening among African-American and white male veterans. Am J Prev Med. 2005, 28 (5): 479-482. 10.1016/j.amepre.2005.02.002.CrossRefPubMed Dolan NC, Ferreira MR, Fitzgibbon ML, Davis TC, Rademaker AW, Liu D, Lee J, Wolf M, Schmitt BP, Bennett CL: Colorectal cancer screening among African-American and white male veterans. Am J Prev Med. 2005, 28 (5): 479-482. 10.1016/j.amepre.2005.02.002.CrossRefPubMed
49.
go back to reference Colorectal cancer test use among persons aged > or = 50 years – United States, 2001. MMWR Morb Mortal Wkly Rep. 2003, 52 (10): 193-196. Colorectal cancer test use among persons aged > or = 50 years – United States, 2001. MMWR Morb Mortal Wkly Rep. 2003, 52 (10): 193-196.
50.
go back to reference Dominitz JA, Samsa GP, Landsman P, Provenzale D: Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer. 1998, 82: 2312-2320. 10.1002/(SICI)1097-0142(19980615)82:12<2312::AID-CNCR3>3.0.CO;2-U.CrossRefPubMed Dominitz JA, Samsa GP, Landsman P, Provenzale D: Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer. 1998, 82: 2312-2320. 10.1002/(SICI)1097-0142(19980615)82:12<2312::AID-CNCR3>3.0.CO;2-U.CrossRefPubMed
51.
go back to reference De Marco MF, Janssen-Heijnen ML, Heijden van der LH, Coebergh JW: Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer. 2000, 36: 95-99. 10.1016/S0959-8049(99)00221-X.CrossRefPubMed De Marco MF, Janssen-Heijnen ML, Heijden van der LH, Coebergh JW: Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer. 2000, 36: 95-99. 10.1016/S0959-8049(99)00221-X.CrossRefPubMed
52.
go back to reference Gonzalez EC, Ferrante JM, Van Durme DJ, Pal N, Roetzheim RG: Comorbid illness and the early detection of cancer. South Med J. 2001, 94: 913-920.CrossRefPubMed Gonzalez EC, Ferrante JM, Van Durme DJ, Pal N, Roetzheim RG: Comorbid illness and the early detection of cancer. South Med J. 2001, 94: 913-920.CrossRefPubMed
53.
go back to reference Geraci JM, Escalante CP, Freeman JL, Goodwin JS: Comorbid disease and cancer: the need for more relevant conceptual models in health services research. J Clin Oncol. 2005, 23: 7399-7404. 10.1200/JCO.2004.00.9753.CrossRefPubMedPubMedCentral Geraci JM, Escalante CP, Freeman JL, Goodwin JS: Comorbid disease and cancer: the need for more relevant conceptual models in health services research. J Clin Oncol. 2005, 23: 7399-7404. 10.1200/JCO.2004.00.9753.CrossRefPubMedPubMedCentral
54.
go back to reference Fleming ST, Pursley HG, Newman B, Pavlov D, Chen K: Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care. 2005, 43 (2): 132-140. 10.1097/00005650-200502000-00006.CrossRefPubMed Fleming ST, Pursley HG, Newman B, Pavlov D, Chen K: Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care. 2005, 43 (2): 132-140. 10.1097/00005650-200502000-00006.CrossRefPubMed
55.
go back to reference Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM: Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol. 2005, 23 (24): 5814-5830. 10.1200/JCO.2005.01.230.CrossRefPubMedPubMedCentral Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM: Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol. 2005, 23 (24): 5814-5830. 10.1200/JCO.2005.01.230.CrossRefPubMedPubMedCentral
56.
go back to reference Langer CJ: Neglected and underrepresented subpopulations: elderly and performance status 2 patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2006, S126-137. 10.3816/CLC.2006.s.004. Suppl 4 Langer CJ: Neglected and underrepresented subpopulations: elderly and performance status 2 patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2006, S126-137. 10.3816/CLC.2006.s.004. Suppl 4
57.
go back to reference Adams-Campbell LL, Ahaghotu C, Gaskins M, Dawkins FW, Smoot D, Polk OD, Gooding R, DeWitty RL: Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol. 2004, 22: 730-734. 10.1200/JCO.2004.03.160.CrossRefPubMed Adams-Campbell LL, Ahaghotu C, Gaskins M, Dawkins FW, Smoot D, Polk OD, Gooding R, DeWitty RL: Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol. 2004, 22: 730-734. 10.1200/JCO.2004.03.160.CrossRefPubMed
58.
go back to reference Aapro MS, Kohne CH, Cohen HJ, Extermann M: Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist. 2005, 10: 198-204. 10.1634/theoncologist.10-3-198.CrossRefPubMed Aapro MS, Kohne CH, Cohen HJ, Extermann M: Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist. 2005, 10: 198-204. 10.1634/theoncologist.10-3-198.CrossRefPubMed
Metadata
Title
Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems
Authors
S Yousuf Zafar
Amy P Abernethy
David H Abbott
Steven C Grambow
Jennifer E Marcello
James E Herndon II
Krista L Rowe
Jane T Kolimaga
Leah L Zullig
Meenal B Patwardhan
Dawn T Provenzale
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-345

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine